Northrop Grumman Corporation
NOCNorthrop Grumman Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (22 weeks in) while the P/E sits at the 44th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −6.8% year on year, and 125% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Northrop Grumman Corporation trades at $531, building a base and 22 weeks into that stage. That is −11.7% against its own 200-day average. It sits at 12% of a 52-week range of $500 to $756. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is building a base — week 22 of stage 1. At $531 it trades −11.7% versus its 200-day average and sits at 12% of its 52-week range ($500–$756).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +139% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Northrop Grumman Corporation trades at 16.9× P/E, mid-range by its own standards (44th percentile). Its long-run median P/E is 17.4×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 16.9× is mid-range by its own standards (44th percentile), against a long-run median of 17.4× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +2.6% against a −7.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +7.0%/yr price move, ~+1.4%/yr came from earnings growth and ~+5.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Northrop Grumman Corporation reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +72.8% at its peak to +14.2% but is still expanding, ROCE holding at 12.5%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.2% | +4.7% | — | — |
| Profit | +0.2% | −5.2% | — | — |
| EPS | +2.6% | −2.6% | — | — |
| Stock price | −7.4% | +7.0% | +8.7% | +9.7% |
4-Factor Sector Score
44.9/100 — rank 15 of 30 in Aerospace & Defense · 81% evidence confidence
Northrop Grumman Corporation scores 44.9 out of 100 against the 30 companies it is compared with in Aerospace & Defense, ranking 15. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 9.9 + 10.7 + 14.5 + 9.8 = 44.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Northrop Grumman Corporation reported $10.9 B of revenue in the Jun 26 quarter, +5.1% year on year. That is the 5th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.1% a year. The last full year, FY25, came in at $42.0 B. The last four reported quarters add to $42.9 B.
FY25 revenue came in at $42.0 B (+2.2% on the year), capping 4 years at 4.1% compound. The latest quarter (Jun 26) printed $10.9 B, +5.1% year on year — the 5th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +5.8% growth against the decade's 4.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +5.9% over the last 4 quarters against +2.6%/yr over the last 8 — accelerating; TTM profit +14.2% vs +40.5%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Northrop Grumman Corporation's operating margin is 10.1% in the Jun 26 quarter, −3.7 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.5% to 15.8%. The current quarter sits inside that band.
The latest quarter's operating margin is 10.1%, −3.7 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 6.5%–15.8%.
🚨 Why the margin moved: operating margin went −3.7 pp year on year while gross margin went −1.9 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Northrop Grumman Corporation earned $1.1 B of net profit in the Jun 26 quarter, −6.8% year on year. Full-year FY25 profit was $4.2 B. The 4-year compound rate is −12.1%. That is 10.0% of the quarter's revenue. The same quarter a year earlier earned $1.2 B. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was $1.1 B, −6.8% year on year. On the full year, FY25 printed $4.2 B (+0.2%), and the 4-year compound rate is −12.1%.
🚨 Why profit moved: revenue contributed +5.1% and the margin −3.7 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +24.2% vs revenue +5.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 125% of Northrop Grumman Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $4.8 B of operating cash against $4.2 B of profit. After $1.4 B of capital spending, $3.3 B was left as free cash.
FY25: operating cash of $4.8 B against reported profit of $4.2 B, leaving free cash of $3.3 B after $1.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 125% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Northrop Grumman Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $5.0 B over the last 3 years. Averaged over those years that is 4.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $5.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Northrop Grumman Corporation earns a ROE of 25% in FY25. That is up from a trough of 14% in FY23. Return on invested capital clears the cost of that capital by +11.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.0% net margin on 0.82× asset turns.
FY25 ROE is 25%, recovered from a FY23 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 10.0% net margin × 0.82× asset turns × 3.08× balance-sheet leverage ≈ 25.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 15.0% − 3.6% = a +11.4 pp spread. The 3.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Northrop Grumman Corporation paid $9.40 per share over the last four reported quarters. The most recent declaration was $2.47 for Jun 26. Against the current price of $531 that is a trailing yield of 1.77%, measured on dividends already paid rather than on a forecast.
Northrop Grumman Corporation paid $9.40 per share across the last four reported quarters, most recently $2.47 for Jun 26. Against the current price of $531 the trailing twelve months work out to 1.77% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Northrop Grumman Corporation carries total debt of $16.3 B against shareholder equity of $17.9 B as of Jun 26, a debt-to-equity of 0.91. On the annual view that ratio went from 1.11 in FY21 to 1.02 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $16.3 B against shareholder equity of $17.9 B — a debt-to-equity of 0.91. On the annual view, debt-to-equity went from 1.11 (FY21) to 1.02 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
1.7% of Northrop Grumman Corporation's tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 3.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 1.7% of the float is sold short, and at typical trading volumes it would take about 3.6 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Northrop Grumman Corporation: the Z-score reads 3.33. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.33 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.33.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Lockheed Martin CorporationLMT | 72.1/100Favorable setup81% evidence | TURNING | 25.6/35 Revenue 7.2% · PAT 49.5% · OPM change 8.3 pp 83% evidence | 14.5/25 ROCE 6.8% · OPM 12.4% 76% evidence | 16.1/20 P/E 18.7× · PEG 0.35 65% evidence | 15.9/20 RS sector 5.2% · RS bench -8% · 1Y 13.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 14.5 + 16.1 + 15.9 = 72.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2RTX CorporationRTX | 65.8/100Favorable setup81% evidence | BREAKING OUT | 21.5/35 Revenue 11.8% · PAT 26.1% · OPM change 1.2 pp 83% evidence | 15.2/25 ROCE 10.4% · OPM 12.7% 76% evidence | 12.1/20 P/E 33× · PEG 1.33 65% evidence | 17.0/20 RS sector 10.7% · RS bench -2.8% · 1Y 24.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 15.2 + 12.1 + 17 = 65.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3HEICO CorporationHEI | 60.0/100Mixed-positive evidence81% evidence | ASLEEP | 24.3/35 Revenue 18.8% · PAT 30.2% · OPM change 2.9 pp 83% evidence | 14.7/25 ROCE 4.3% · OPM 25.5% 76% evidence | 10.4/20 P/E 48.2× · PEG 1.56 65% evidence | 10.6/20 RS sector -0.7% · RS bench -12.7% · 1Y -6.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.4 + 10.6 = 60 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Elbit Systems Ltd.ESLT | 59.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.4/35 Revenue 13.7% · PAT 60.2% · OPM change 1.6 pp 83% evidence | 11.7/25 ROCE 3.1% · OPM 9.6% 76% evidence | 11.7/20 P/E 57.2× · PEG 1.13 65% evidence | 14.0/20 RS sector 12.2% · RS bench -1.9% · 1Y 51.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 11.7 + 11.7 + 14 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Howmet Aerospace Inc.HWM | 59.7/100Mixed-positive evidence81% evidence | ASLEEP | 24.6/35 Revenue 18.1% · PAT 33.9% · OPM change 2.5 pp 83% evidence | 16.3/25 ROCE 7% · OPM 27.9% 76% evidence | 9.0/20 P/E 57.9× · PEG 1.62 65% evidence | 9.8/20 RS sector 2.6% · RS bench -9.8% · 1Y 19.7%3 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 16.3 + 9 + 9.8 = 59.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Embraer S.A.EMBJ | 58.3/100Mixed-positive evidence66% evidence | BREAKING OUT | 16.5/35 Revenue 20% · PAT -22.2% · OPM change 1 pp 53% evidence | 7.6/25 ROCE 1.1% · OPM 5.6% 57% evidence | 14.2/20 P/E 54.9× · PEG 0.51 65% evidence | 20.0/20 RS sector 21% · RS bench 6.4% · 1Y 27.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 7.6 + 14.2 + 20 = 58.3 · Decision use: Price leads the evidence: RS versus the benchmark is 6.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7General Dynamics CorporationGD | 56.7/100Thin evidence · provisional58% evidence | FADING | 17.0/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 12.5/25 ROCE 3.7% · OPM 10.4% 76% evidence | 11.0/20 P/E 22.8× · PEG — 15% evidence | 16.2/20 RS sector 8.7% · RS bench -4.4% · 1Y 11.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 12.5 + 11 + 16.2 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Hexcel CorporationHXL | 56.0/100Thin evidence · provisional56% evidence | FADING | 20.8/35 Revenue — · PAT — · OPM change 1.8 pp 39% evidence | 10.8/25 ROCE 2.9% · OPM 11.5% 76% evidence | 10.0/20 P/E 50.3× · PEG — 15% evidence | 14.4/20 RS sector 14.1% · RS bench 0.4% · 1Y 47.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 10.8 + 10 + 14.4 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9GE AerospaceGE | 54.5/100Mixed-positive evidence81% evidence | ASLEEP | 19.4/35 Revenue 21.7% · PAT 16.2% · OPM change -0.3 pp 83% evidence | 16.4/25 ROCE 11.7% · OPM 20.6% 76% evidence | 7.3/20 P/E 43.5× · PEG 2.38 65% evidence | 11.4/20 RS sector 4.8% · RS bench -7.8% · 1Y 3.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 16.4 + 7.3 + 11.4 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Curtiss-Wright CorporationCW | 52.7/100Mixed-positive evidence81% evidence | ASLEEP | 21.8/35 Revenue 10.5% · PAT 20% · OPM change 1.5 pp 83% evidence | 19.5/25 ROCE 17.4% · OPM 19.4% 76% evidence | 7.4/20 P/E 51.7× · PEG 2.28 65% evidence | 4.0/20 RS sector -6.4% · RS bench -17.9% · 1Y 10.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 19.5 + 7.4 + 4 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Woodward, Inc.WWD | 52.6/100Thin evidence · provisional56% evidence | ASLEEP | 20.4/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence | 14.3/25 ROCE 4.9% · OPM 14.7% 76% evidence | 9.9/20 P/E 50.5× · PEG — 15% evidence | 8.0/20 RS sector -0.2% · RS bench -12.5% · 1Y 33.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 14.3 + 9.9 + 8 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Loar Holdings Inc.LOAR | 50.3/100Thin evidence · provisional56% evidence | ASLEEP | 18.7/35 Revenue 26.3% · PAT 91.7% · OPM change -1.3 pp 53% evidence | 10.3/25 ROCE 1.8% · OPM 21.5% 57% evidence | 9.1/20 P/E 80.7× · PEG — 15% evidence | 12.2/20 RS sector -0.4% · RS bench -12.4% · 1Y -19.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 10.3 + 9.1 + 12.2 = 50.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Leonardo DRS, Inc.DRS | 49.0/100Thin evidence · provisional56% evidence | ASLEEP | 20.3/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence | 11.8/25 ROCE 3.3% · OPM 9.1% 76% evidence | 10.7/20 P/E 35.9× · PEG — 15% evidence | 6.2/20 RS sector -4% · RS bench -15.9% · 1Y -10.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 11.8 + 10.7 + 6.2 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Textron Inc.TXT | 46.2/100Thin evidence · provisional56% evidence | BASING | 15.9/35 Revenue — · PAT — · OPM change -0.8 pp 39% evidence | 9.3/25 ROCE 2% · OPM 6.3% 76% evidence | 11.3/20 P/E 17.4× · PEG — 15% evidence | 9.7/20 RS sector -2.9% · RS bench -14.9% · 1Y -3.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 9.3 + 11.3 + 9.7 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Northrop Grumman Corporationthis pageNOC | 44.9/100Mixed-negative evidence81% evidence | TURNING | 9.9/35 Revenue 5.9% · PAT 14% · OPM change -3.7 pp 83% evidence | 10.7/25 ROCE 3% · OPM 10.1% 76% evidence | 14.5/20 P/E 16.2× · PEG 1.01 65% evidence | 9.8/20 RS sector -5.5% · RS bench -17.5% · 1Y -7.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.9 + 10.7 + 14.5 + 9.8 = 44.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 16Axon Enterprise, Inc.AXON | 44.8/100Mixed-negative evidence71% evidence | BREAKING OUT | 20.0/35 Revenue 34.6% · PAT -39% · OPM change 5.4 pp 83% evidence | 6.4/25 ROCE 0.9% · OPM 5.2% 76% evidence | 8.6/20 P/E 232.6× · PEG — 15% evidence | 9.8/20 RS sector -6.2% · RS bench -17.4% · 1Y -39.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 6.4 + 8.6 + 9.8 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17CAE Inc.CAE | 44.4/100Mixed-negative evidence66% evidence | ASLEEP | 10.7/35 Revenue 4.4% · PAT -22.4% · OPM change -7.6 pp 53% evidence | 10.7/25 ROCE 2% · OPM 12.9% 57% evidence | 14.7/20 P/E 37.3× · PEG 0.68 65% evidence | 8.3/20 RS sector -6.5% · RS bench -18.1% · 1Y -14%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.7 + 14.7 + 8.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18The Boeing CompanyBA | 43.8/100Mixed-negative evidence64% evidence | ASLEEP | 19.8/35 Revenue 24.8% · PAT — · OPM change 1.4 pp 62% evidence | 4.1/25 ROCE 0.3% · OPM 0.6% 76% evidence | 9.0/20 P/E 93.7× · PEG — 15% evidence | 10.9/20 RS sector -1.2% · RS bench -13.4% · 1Y -6.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 4.1 + 9 + 10.9 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Huntington Ingalls Industries, Inc.HII | 43.6/100Thin evidence · provisional56% evidence | BASING | 16.6/35 Revenue — · PAT — · OPM change -0.9 pp 39% evidence | 9.4/25 ROCE 2.2% · OPM 5% 76% evidence | 11.4/20 P/E 16.7× · PEG — 15% evidence | 6.2/20 RS sector -11.8% · RS bench -23.2% · 1Y 1.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 9.4 + 11.4 + 6.2 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20StandardAero, Inc.SARO | 42.9/100Thin evidence · provisional56% evidence | ASLEEP | 18.4/35 Revenue 15% · PAT 100% · OPM change -0.2 pp 53% evidence | 9.2/25 ROCE 2.8% · OPM 8.8% 57% evidence | 10.9/20 P/E 29.4× · PEG — 15% evidence | 4.4/20 RS sector -10.4% · RS bench -21.6% · 1Y -16.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 9.2 + 10.9 + 4.4 = 42.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21TransDigm Group IncorporatedTDG | 41.7/100Mixed-negative evidence81% evidence | ASLEEP | 15.3/35 Revenue 16.6% · PAT 10.3% · OPM change -1.6 pp 83% evidence | 15.9/25 ROCE 5.5% · OPM 44.8% 76% evidence | 5.3/20 P/E 40.2× · PEG 4.28 65% evidence | 5.2/20 RS sector -9.4% · RS bench -20.5% · 1Y -15.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 15.9 + 5.3 + 5.2 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Rocket Lab CorporationRKLB | 40.5/100Mixed-negative evidence61% evidence | ASLEEP | 25.1/35 Revenue 52.6% · PAT — · OPM change 16.7 pp 62% evidence | 3.1/25 ROCE -2.4% · OPM -24.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.3/20 RS sector -9.3% · RS bench -20.5% · 1Y 33.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.1 + 3.1 + 10 + 2.3 = 40.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.3% and the one-year return is 33.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 23L3Harris Technologies, Inc.LHX | 39.8/100Thin evidence · provisional58% evidence | BASING | 17.3/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 10.2/25 ROCE 1.9% · OPM 11.1% 76% evidence | 8.8/20 P/E 96× · PEG — 15% evidence | 3.5/20 RS sector -13% · RS bench -24% · 1Y -11.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 10.2 + 8.8 + 3.5 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24FTAI Aviation Ltd.FTAI | 38.4/100Thin evidence · provisional56% evidence | ASLEEP | 12.8/35 Revenue — · PAT — · OPM change -9.6 pp 39% evidence | 13.4/25 ROCE 5% · OPM 20.5% 76% evidence | 9.2/20 P/E 58.8× · PEG — 15% evidence | 3.0/20 RS sector -8% · RS bench -19.9% · 1Y 6.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 13.4 + 9.2 + 3 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25AeroVironment, Inc.AVAV | 37.7/100Mixed-negative evidence71% evidence | BASING | 17.6/35 Revenue 100% · PAT -702.3% · OPM change 3.9 pp 83% evidence | 6.1/25 ROCE 1.8% · OPM 8.9% 76% evidence | 8.7/20 P/E 97.8× · PEG — 15% evidence | 5.3/20 RS sector -28.4% · RS bench -37.4% · 1Y -43.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 6.1 + 8.7 + 5.3 = 37.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Kratos Defense & Security Solutions, Inc.KTOS | 37.1/100Thin evidence · provisional56% evidence | ASLEEP | 18.2/35 Revenue 21.9% · PAT 50% · OPM change -0.9 pp 53% evidence | 6.4/25 ROCE 0.2% · OPM 1.3% 57% evidence | 8.5/20 P/E 423.2× · PEG — 15% evidence | 4.0/20 RS sector -30.2% · RS bench -39.4% · 1Y -41.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 6.4 + 8.5 + 4 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27BWX Technologies, Inc.BWXT | 34.2/100Adverse evidence66% evidence | ASLEEP | 16.4/35 Revenue 21.4% · PAT 19% · OPM change -1.8 pp 53% evidence | 11.2/25 ROCE 2.7% · OPM 9.9% 57% evidence | 5.3/20 P/E 54.7× · PEG 2.86 65% evidence | 1.3/20 RS sector -18.7% · RS bench -28.8% · 1Y -16.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 11.2 + 5.3 + 1.3 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Moog Inc.MOG-B | 53.2/100Thin evidence · provisional33% evidence | FADING | 19.5/35 Revenue — · PAT — · OPM change 1 pp 32% evidence | 13.1/25 ROCE 4.4% · OPM 10.8% 76% evidence | 10.6/20 P/E 36.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y 86.1%9 of 11 weeks ahead 0% evidence |
| Exact sum: 19.5 + 13.1 + 10.6 + 10 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Honeywell Aerospace Inc.HONA | 42.7/100Thin evidence · provisional48% evidence | ASLEEP | 7.2/35 Revenue 10.1% · PAT -32.7% · OPM change -10.5 pp 83% evidence | 15.5/25 ROCE 8.9% · OPM 12.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence |
| Exact sum: 7.2 + 15.5 + 10 + 10 = 42.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Space Exploration Technologies Corp.SPCX | 39.8/100Thin evidence · provisional33% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change 17.2 pp 39% evidence | 3.4/25 ROCE -1.6% · OPM -1.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 1 week ahead 0% evidence |
| Exact sum: 16.4 + 3.4 + 10 + 10 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Northrop Grumman Corporation's stock price today?
Northrop Grumman Corporation trades at $531, −7.4% over the past year. The company is valued at $75.0 B. The stock sits at 12% of its 52-week range of $500–$756, −11.7% versus its 200-day average. On the tape, the price is building a base, 22 weeks in. — as of 17 September 2026.
What were Northrop Grumman Corporation's latest quarterly results?
Northrop Grumman Corporation reported revenue of $10.9 B and net profit of $1.1 B for the Jun 26 quarter. Revenue rose 5.1% and profit fell 6.8% year on year. Earnings per share were $7.68. The operating margin was 10.1%, 3.7 pp lower than a year earlier. — as of 17 September 2026.
What is Northrop Grumman Corporation's revenue?
Northrop Grumman Corporation reported revenue of $10.9 B in the Jun 26 quarter, +5.1% year on year. For the full FY25 fiscal year, revenue was $42.0 B (+2.2%). Over the last 4 years revenue compounded at 4.1% a year. — as of 17 September 2026.
What is Northrop Grumman Corporation's profit?
Northrop Grumman Corporation earned $1.1 B of net profit in the Jun 26 quarter, −6.8% year on year. Full-year FY25 profit was $4.2 B. The operating margin ran 10.1% in the latest quarter. — as of 17 September 2026.
What is Northrop Grumman Corporation's market cap?
Northrop Grumman Corporation's market capitalisation is $75.0 B at a stock price of $531. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Northrop Grumman Corporation's P/E ratio?
Northrop Grumman Corporation trades at a P/E of 16.9×, at the 44th percentile of its own 5-year range, against a long-run median of 17.4×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Northrop Grumman Corporation pay a dividend?
Yes — Northrop Grumman Corporation declared $2.47 per share for Jun 26, and $9.40 per share across the last four reported quarters. — as of 17 September 2026.
What is Northrop Grumman Corporation's dividend per share?
Northrop Grumman Corporation's most recently declared dividend is $2.47 per share for Jun 26, giving $9.40 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Northrop Grumman Corporation's dividend yield?
Northrop Grumman Corporation's trailing dividend yield is 1.77%: $9.40 declared per share across the last four reported quarters, against a share price of $531. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is Northrop Grumman Corporation overvalued?
On its own history, Northrop Grumman Corporation looks mid-range: its P/E of 16.9× sits at the 44th percentile of its 5-year range (long-run median 17.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Northrop Grumman Corporation growing?
Not right now — Northrop Grumman Corporation's latest numbers are shrinking: latest-quarter revenue +5.1% year on year, profit −6.8%, and the margin −3.7 pp at 10.1%. The 4-year compound rates are 4.1% (revenue) and −12.1% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Northrop Grumman Corporation performing?
Northrop Grumman Corporation is building a base, 22 weeks in. Its latest quarter's revenue rose 5.1% and profit fell 6.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Northrop Grumman Corporation in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +72.8% at its peak to +14.2% but is still expanding, ROCE holding at 12.5%. The read comes from the last 12 quarters of growth (revenue growth +5.9% latest, profit growth +14.2% latest, eps growth +16.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Northrop Grumman Corporation in an uptrend?
No — the price is building a base (week 22 of stage 1), trading −11.7% versus its 200-day average and at 12% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Northrop Grumman Corporation beating the market?
On recent form, yes — Northrop Grumman Corporation has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +139% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Northrop Grumman Corporation's stock price go up?
This page publishes no price forecast for Northrop Grumman Corporation. What it measures instead: the stock price is $531, the price is building a base 22 weeks in. Its P/E of 16.9× sits at the 44th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against Northrop Grumman Corporation?
No — short interest is 1.7% of Northrop Grumman Corporation's tradable float, about 3.6 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Northrop Grumman Corporation have too much debt?
It is moderate — Northrop Grumman Corporation's debt-to-equity is 0.95. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Northrop Grumman Corporation's capex?
Northrop Grumman Corporation spent $5.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.4 B. — as of 17 September 2026.
What is Northrop Grumman Corporation's cash flow?
Northrop Grumman Corporation generated $4.8 B of operating cash flow in FY25 and $3.3 B of free cash flow after $1.4 B of capital spending. Reported profit that year was $4.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Northrop Grumman Corporation's profit real cash?
Yes — over the last 3 fiscal years, 125% of Northrop Grumman Corporation's reported profit arrived as operating cash. In FY25, operating cash was $4.8 B against reported profit of $4.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Northrop Grumman Corporation?
On the balance sheet, the Z-score reads 3.33 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Northrop Grumman Corporation in its business cycle?
Northrop Grumman Corporation's FY25 operating margin was 10.8%, against a 5-year band of 6.5%–15.8%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 10.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Northrop Grumman Corporation story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Northrop Grumman Corporation a stock worth studying right now?
This is not investment advice. The machine read: Northrop Grumman Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!